SUPPLEMENTARY INFORMATION



Figure S1: Treatment with a monoclonal antibody to CD25 depletes more than 50% of Foxp3⁺ T-reg. $1/6^{-/-}$ ×Foxp3gfp.KI mice were treated with rat IgG1 (non-depleted) or anti-CD25 antibody (PC61) by intraperitoneal injection of 500 µg on days -5 and -3 prior to immunisation with MOG₃₅₋₅₅ in complete Freund's adjuvant. Seven days after immunisation, lymph node cells were isolated, stained for CD4 and analysed by flow cytometry for the presence of CD4⁺Foxp3/GFP⁺ T-cells. The numbers in the quadrants represent percentages.

Figure S2



Figure S2: II6^{-/-} **mice do not exhibit residual IL-6 production**. Wildtype, *II6*^{-/-}, or Treg-depleted (anti-CD25) *II6*^{-/-} mice were immunised with MOG_{35-55} emulsified in complete Freund's adjuvant. Six days after immunisation, splenocytes were isolated and re-stimulated in vitro with increasing concentrations of purified protein derivative from M. tuberculosis (PPD). Since M. tuberculosis is the major constituent of the immunising emulsion, we re-activated the splenocyte cultures with PPD to induce a maximum response and to determine whether under these conditions $Il6^{-/-}$ mice would show any indication of residual IL-6 production. After 48 h supernatants were collected and assayed for IL-10, TNF, and IL-6 by cytometric bead array. Splenocytes from $Il6^{-/-}$ mice continued to produce IL-10 and TNF, but failed to produce any IL-6. Furthermore, prior depletion of T-reg did not result in IL-6 production from splenocytes of $Il6^{-/-}$ mice either.



Figure S5



Figure S4: T-cells are the major source of IL-21 in T-reg-depleted II6^{-/-} **mice.** $Il6^{-/-}$ mice were depleted of T-reg by injection of anti-CD25 antibody followed by immunisation with MOG₃₅₋₅₅ emulsified in CFA (as described in Figure 2). Seven days after immunisation, different cell types were purified from pooled draining lymph node cells and splenocytes by flow cytometry sorting. T-cells

(Thy1.2⁺) were activated with PMA/ionomycin and B cells (CD19⁺), dendritic cells (CD11c⁺, DCs), macrophages (CD11b⁺, MØ), and NK cells (NK1.1⁺) were activated with LPS before isolation of RNA for quantitative RT-PCR to determine the cell type-specific expression of IL-17 and IL-21. For comparison, T-cells and B cells were also analysed without *in vitro*-activation.



Figure S5: *In vivo*-blocking of IL-21 inhibits the generation of Th17 cells in Treg-depleted II6^{-/-} mice. *Il6*^{-/-} mice were treated with control rat IgG1 (nondepleted) or with anti-CD25 antibody to deplete T-reg (T-reg-depleted) followed by immunisation with MOG₃₅₋₅₅ emulsified in complete Freund's adjuvant. The T-reg depleted groups were either treated with PBS (control) or with IL-21 receptor-Ig (4 times 200 µg intraperitoneally every other day, starting on the day of immunisation) in order to block IL-21-activity *in vivo*. On day 7 after immunisation, draining lymph node cells were isolated, stimulated with PMA/ionomycin, stained for intracellular IL-17 and IFN- γ , and analysed by flow cytometry. The gate is set on CD4⁺Foxp3/GFP⁻ T-cells. Numbers indicate percentages.